Toward in vivo proof of binding of 18F-labeled inhibitor [18F]TRACK to peripheral tropomyosin receptor kinases

Background Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are a family of tyrosine kinases primarily expressed in neuronal cells of the brain. Identification of oncogenic alterations in Trk expression as a driver in multiple tumor types has increased interest in their role in human cancers. Recentl...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:EJNMMI research 2022-07, Vol.12 (1), p.46-46, Article 46
Hauptverfasser: Wuest, Melinda, Bailey, Justin J., Dufour, Jennifer, Glubrecht, Darryl, Omana, Vanessa, Johnston, Tom H., Brotchie, Jonathan M., Schirrmacher, Ralf
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Tropomyosin receptor kinases (TrkA, TrkB, TrkC) are a family of tyrosine kinases primarily expressed in neuronal cells of the brain. Identification of oncogenic alterations in Trk expression as a driver in multiple tumor types has increased interest in their role in human cancers. Recently, first- and second-generation 11 C and 18 F-labeled Trk inhibitors, e.g., [ 18 F]TRACK, have been developed. The goal of the present study was to analyze the direct interaction of [ 18 F]TRACK with peripheral Trk receptors in vivo to prove its specificity for use as a functional imaging probe. Methods In vitro uptake and competition experiments were carried out using the colorectal cancer cell line KM12. Dynamic PET experiments were performed with [ 18 F]TRACK, either alone or in the presence of amitriptyline, an activator of Trk, entrectinib, a Trk inhibitor, or unlabeled reference compound TRACK in KM12 tumor-bearing athymic nude mice as well as B6129SF2/J and corresponding B6;129S2- Ntrk2 tm1Bbd /J mice. Western blot and immunohistochemistry experiments were done with KM12 tumors, brown adipose tissue (BAT), and brain tissue samples. Results Uptake of [ 18 F]TRACK was increasing over time reaching 208 ± 72% radioactivity per mg protein ( n  = 6/2) after 60 min incubation time. Entrectinib and TRACK competitively blocked [ 18 F]TRACK uptake in vitro (IC 50 30.9 ± 3.6 and 29.4 ± 9.4 nM; both n  = 6/2). [ 18 F]TRACK showed uptake into KM12 tumors (SUV mean,60 min 0.43 ± 0.03; n  = 6). Tumor-to-muscle ratio reached 0.9 (60 min) and 1.2 (120 min). In TrkB expressing BAT, [ 18 F]TRACK uptake reached SUV mean,60 min 1.32 ± 0.08 ( n  = 7). Activation of Trk through amitriptyline resulted in a significant radioactivity increase of 21% in KM12 tumor (SUV mean,60 min from 0.53 ± 0.01 to 0.43 ± 0.03; n  = 6; p   TrkB in whole brain. WB analysis showed sevenfold higher TrkB expression in BAT versus KM12 tumor tissue. Conclusion The present data show that radiotracer [ 18 F]TRACK can target peripheral Trk receptors in human KM12 colon cancer as well as brown adipose tissue as confirmed through in vitro and in vivo blocking experiments. Higher TrkB versus TrkA protein expression was detected in brown adipose tissue of mice confirming a peripheral functional role of brain-derived
ISSN:2191-219X
2191-219X
DOI:10.1186/s13550-022-00915-w